Tibet Haisco Pharmaceutical Co. Ltd. has divulged myosin-2 (MYH2) inhibitors reported to be useful for the treatment of muscular dystrophy.

Tibet Haisco Pharmaceutical Co. Ltd. has disclosed integrin α4β7 (LPAM-1) and/or α4β1 (ITGA4; VLA-4) antagonists reported to be useful for the treatment of inflammatory disorders.

A Tibet Haisco Pharmaceutical Co. Ltd. patent describes new phosphodiesterase PDE4B inhibitors potentially useful for the treatment of cancer, chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis.

Tibet Haisco Pharmaceutical Co. Ltd. has prepared new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to androgen receptor variant 7 (AR-v7)-targeting moiety.